Kallyope
Founded Year
2015Stage
Grant | AliveTotal Raised
$487.2MLast Raised
$8.2M | 2 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-30 points in the past 30 days
About Kallyope
Kallyope focused on health challenges within the neurological and metabolic disease sectors. The company specializes in the discovery and development of therapeutics aimed at treating conditions such as type 2 diabetes, obesity, migraine, and other neurological and gastrointestinal disorders. Kallyope's proprietary Klarity platform is used to facilitate the creation of these oral therapies. It was founded in 2015 and is based in New York, New York.
Loading...
Loading...
Expert Collections containing Kallyope
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Kallyope is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,276 items
Game Changers 2018
36 items
Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.
Kallyope Patents
Kallyope has filed 18 patents.
The 3 most popular patent topics include:
- autoimmune diseases
- gastrointestinal tract disorders
- inflammations
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/16/2022 | 4/1/2025 | Gastrointestinal tract disorders, Inflammations, Autoimmune diseases, Rare diseases, Diseases of intestines | Grant |
Application Date | 5/16/2022 |
|---|---|
Grant Date | 4/1/2025 |
Title | |
Related Topics | Gastrointestinal tract disorders, Inflammations, Autoimmune diseases, Rare diseases, Diseases of intestines |
Status | Grant |
Latest Kallyope News
Apr 14, 2025
Kallyope Launches with $44M in Series A Funding Kallyope, Inc. , a New York City-based biotech company focused on harnessing the potential of the gut-brain axis, launched with $44m in Series A funding. Backers included Polaris Partners, Lux Capital, Illumina, Inc., The Column Group, Tony Evnin, Ph.D., and Alexandria Venture Investments. Founded by Charles Zuker, Ph.D., Tom Maniatis, Ph.D. and Richard Axel, M.D., and led by CEO Nancy Thornberry, Kallyope leverages technologies including sequencing, genetics, circuit mapping, neural imaging and bioinformatics to provide an understanding of gut-brain biology that will lead to novel therapeutics and products that improve human health and nutrition. The company is based at the Alexandria Center® for Life Science in New York City, a collaborative life science campus in the heart of Manhattan. Members of the advisory board include Michael Brown, M.D., Nobel laureate, Joseph Goldstein, M.D., Nobel laureate and Richard Scheller, Ph.D.,Lasker Award FinSMEs
Kallyope Frequently Asked Questions (FAQ)
When was Kallyope founded?
Kallyope was founded in 2015.
Where is Kallyope's headquarters?
Kallyope's headquarters is located at 430 East 29th Street, New York.
What is Kallyope's latest funding round?
Kallyope's latest funding round is Grant.
How much did Kallyope raise?
Kallyope raised a total of $487.2M.
Who are the investors of Kallyope?
Investors of Kallyope include Bill & Melinda Gates Foundation, Alexandria Venture Investments, The Column Group, Polaris Partners, Lux Capital and 15 more.
Loading...
Loading...